European Commission logo
English English
CORDIS - EU research results

Article Category

Content archived on 2023-03-23

Article available in the following languages:


Target Health Inc. joins DAI-SYS CRO Plus to collaborate in international clinical trial projects

US based Contract Research Organisation Target Health Inc. has recently joined DAI-SYS CRO Plus in order to conduct international clinical trial projects.

NEW YORK, 30th of May 2014—US based Contract Research Organisation Target Health Inc. has recently joined DAI-SYS CRO Plus in order to conduct international clinical trial projects. Target Health is a full service e*CRO committed to improving the way companies run clinical trials. By successfully applying Target e*CRF® in over 300 clinical trials, Target Health strives to optimize the life cycle of drug, biologic and device development with expertise, leadership, innovation and teamwork. “We are very excited about welcoming Target Health as a new member of DAI-SYS CRO Plus” says DAI-SYS Chairperson Dr Helen Allars, “through our CRO Datapharm Australia we met Target Health a number of years ago through the DIA conferences. We share an interest for working to the highest standards of ethical conduct and integrity, as well as delivering consistent performance through industry knowledge, experience and use of technology. As members of DAI-SYS, we look forward to the opportunity of collaborating with Target Health on the next international clinical trial project involving the US”. “Target Health is very pleased to be part of DAI-SYS CRO Plus and looks forward to our global collaboration,” says Jules, T. Mitchel, MBA, PhD, President of Target Health. “Collaborations like this can only make the world of drug and device development more consistent and coherent, and accelerate the marketing approval of meaningful drugs for the betterment of all and the common good.” About Target Health Target Health Inc. is a New York City based CRO with staff dedicated to all aspects of Drug and Device Development including: Strategic Planning Regulatory Affairs, Clinical Research Management, Biostatistics, Data Management and Medical Writing. In addition, Target Health is an industry leader in the development of innovative web-based software tools for clinical trials. These tools provide sponsors with a significant productivity edge, and allow for the paperless clinical trial. The toolbox includes, but is not limited to: Electronic Data Capture (Targe e*CRF®; EDC), Target e*CTR® (eClinical Trial Record; eSource); Target Document® (for eTMF) and Risk-Based and Central Monitoring. About DAI-SYS DAI-SYS CRO Plus - the DAI-SYS Chain - is a group of selected CROs based in different countries in Europe, the US and Asia Pacific. All members are experts in their local area and offer high industry standards. DAI-SYS CRO Plus members are committed to provide their services in their local currency as required by international clinical trial projects run by DAI-SYS. DAI-SYS core business is to carry out clinical trials work anywhere in the world, from protocol development to the final report (i.e. Full Service). By combining the knowledge and experience of locally based CROs, DAI-SYS offers clients the possibility of running local and multi-national clinical trials that are more economical utilizing appropriate technology, innovative management and financial approaches. For any enquiries please contact: Luke Edington, Business Development Associate Ph +612 9719 2800 Cell +61408 206 011 Email MEET WITH DAI-SYS/DATAPHARM AUSTRALIA AT DIA 2014 – Booth 730 OR Warren M. Pearlson, Director Business Development Ph 212-681-2100 ext. 104 Cell 631-455-5973 Email MEET WITH TARGET HEALTH AT DIA 2014 – Booth 1935


Clinical Trials


Austria, Australia, Belgium, Bulgaria, Cyprus, Czechia, Germany, Denmark, Estonia, Greece, Spain, Finland, France, Hungary, Ireland, Italy, Lithuania, Luxembourg, Latvia, Malta, Netherlands, Poland, Portugal, Romania, Sweden, United Kingdom